ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting

100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good tolerability70% of patients derived to Hematopoietic Stem Cell Transplantation (HSCT) 67% CCR at the expansion dose in study evaluating iadademstat plus gilterinib in FLT3-mutated relapsed/refractory AML patients; 47% CR+CRhTreatment was safe and well tolerated MADRID, SPAIN and CAMBRIDGE, Mass. ...